Biopharma Credit Plc Stock Net Income
| BOPCFDelisted Stock | USD 0.92 0.00 0.00% |
As of the 12th of February 2026, BioPharma Credit shows the Standard Deviation of 1.51, risk adjusted performance of 0.112, and Mean Deviation of 0.6709. BioPharma Credit PLC technical analysis gives you the methodology to make use of historical prices and volume patterns to determine a pattern that approximates the direction of the firm's future prices. Please confirm BioPharma Credit PLC variance, maximum drawdown, as well as the relationship between the Maximum Drawdown and skewness to decide if BioPharma Credit PLC is priced correctly, providing market reflects its regular price of 0.92 per share. Given that BioPharma Credit is a hitting penny stock territory we recommend to closely look at its jensen alpha.
BioPharma Credit's financial statements offer valuable quarterly and annual insights to potential investors, highlighting the company's current and historical financial position, overall management performance, and changes in financial standing over time. Key fundamentals influencing BioPharma Credit's valuation are provided below:BioPharma Credit PLC does not presently have any fundamental signals for analysis. This module does not cover all equities due to inconsistencies in global equity categorizations. Continue to Equity Screeners to view more equity screening tools. BioPharma |
Search Suggestions
| B | Barrick Mining | Company |
| BNJ | Brookfield Finance 450 | Company |
| BBN | Blackrock Taxable Municipal | Fund |
| BU | Defiance Daily Target | ETF |
| BKX | KBW Bank | Index |
| B2 | B Network | Cryptocurrency |
| B5341FAB7 | KBCBB 5796 19 JAN 29 | Corporate Bond |
| BZUSD | Brent Crude Oil | Commodity |
Because income is reported on the Income Statement of a company and is measured in dollars some investors prefer to use Profit Margin, which measures income as a percentage of sales.
CompetitionBased on the recorded statements, BioPharma Credit PLC reported net income of 84.96 M. This is much higher than that of the sector and significantly higher than that of the Net Income industry. The net income for all United States stocks is notably lower than that of the firm.
BioPharma Net Income Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses BioPharma Credit's direct or indirect competition against its Net Income to detect undervalued stocks with similar characteristics or determine the pink sheets which would be a good addition to a portfolio. Peer analysis of BioPharma Credit could also be used in its relative valuation, which is a method of valuing BioPharma Credit by comparing valuation metrics of similar companies.BioPharma Credit is currently under evaluation in net income category among its peers.
BioPharma Fundamentals
| Return On Equity | 0.079 | |||
| Return On Asset | 0.0493 | |||
| Profit Margin | 0.85 % | |||
| Operating Margin | 0.85 % | |||
| Current Valuation | 1.22 B | |||
| Shares Outstanding | 914.25 M | |||
| Shares Owned By Insiders | 7.68 % | |||
| Shares Owned By Institutions | 39.25 % | |||
| Price To Earning | 13.38 X | |||
| Price To Sales | 10.63 X | |||
| Revenue | 127.83 M | |||
| Gross Profit | 103.88 M | |||
| Net Income | 84.96 M | |||
| Cash And Equivalents | 10.44 M | |||
| Cash Per Share | 0.01 X | |||
| Current Ratio | 14.07 X | |||
| Book Value Per Share | 1.01 X | |||
| Cash Flow From Operations | 96.44 M | |||
| Earnings Per Share | 0.06 X | |||
| Beta | 0.23 | |||
| Market Capitalization | 1.36 B | |||
| Last Dividend Paid | 0.07 |
About BioPharma Credit Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze BioPharma Credit PLC's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of BioPharma Credit using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of BioPharma Credit PLC based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Currently Active Assets on Macroaxis
| FSLY | Fastly Class A | |
| MOB | Mobilicom Limited American | |
| CMG | Chipotle Mexican Grill | |
| CSAN | Cosan SA ADR | |
| RKT | Rocket Companies |
Check out Trending Equities to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in services. You can also try the Portfolio Manager module to state of the art Portfolio Manager to monitor and improve performance of your invested capital.
Other Consideration for investing in BioPharma Pink Sheet
If you are still planning to invest in BioPharma Credit PLC check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the BioPharma Credit's history and understand the potential risks before investing.
| Portfolio Rebalancing Analyze risk-adjusted returns against different time horizons to find asset-allocation targets | |
| Commodity Directory Find actively traded commodities issued by global exchanges | |
| Risk-Return Analysis View associations between returns expected from investment and the risk you assume | |
| Sync Your Broker Sync your existing holdings, watchlists, positions or portfolios from thousands of online brokerage services, banks, investment account aggregators and robo-advisors. | |
| Performance Analysis Check effects of mean-variance optimization against your current asset allocation | |
| Investing Opportunities Build portfolios using our predefined set of ideas and optimize them against your investing preferences | |
| Latest Portfolios Quick portfolio dashboard that showcases your latest portfolios | |
| Premium Stories Follow Macroaxis premium stories from verified contributors across different equity types, categories and coverage scope | |
| Price Exposure Probability Analyze equity upside and downside potential for a given time horizon across multiple markets |